Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism RIPK2 inhibitors(Serine/threonine-protein kinase RIPK2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC15H12F2N2O3S |
InChIKeyFFNNRVGCABVLNA-UHFFFAOYSA-N |
CAS Registry2773110-09-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Crohn Disease | Preclinical | United States | 15 Feb 2018 | |
| Multiple Sclerosis | Preclinical | United States | 15 Feb 2018 |





